Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT

Bone Marrow Transplantation

Volumn 46, Issue 1, 2011, Pages 125-131

  Vigano M ^a   Vener, C ^a   Lampertico, P ^a   Annaloro, C ^a   Pichoud, C ^b,c,d   Zoulim, F ^b,c,d   Facchetti, F ^a   Poli, F ^a   Scalamogna, M ^a   Deliliers, G Lambertenghi ^a   Colombo, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HÔTEL DIEU   (France)

Author keywords

BMT; HBsAg; HBVDNA; immunosuppression; stem cells

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; CYCLOSPORIN A; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; VIRUS DNA;

ADD ON THERAPY; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SEROCONVERSION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; ITALY; MALE; MIDDLE AGED; RISK FACTORS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 78651347099     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.70     Document Type: Article

References (37)

1. Horowitz MM. Uses and growth of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Farman SJ (eds). Hematopoietic Cell Transplantation. Blackwell: Cambridge, MA, 1999, 12.
2. Lau GKK, Lee CK, Liang R. Hepatitis B virus infection and bone marrow transplantation. Crit Rev Oncol Hematol 1999; 31: 71-76.
3. Reed EC, Myerson D, Corey L, Meyers JD. Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991; 77: 195-200.
4. Locasciulli A, Bacigalupo A, Van Lint MT, Chemello L, Pontisso P, Occhini D et al. Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: A report of 30 cases. Bone Marrow Transplant 1990; 6: 25-29.
5. Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem. J Clin Oncol 1999; 17: 394-398.
6. Ma SY, Lau GKK, Cheng VCC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma 2003; 44: 1281-1285.
7. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management. Blood 1999; 93: 1127-1136.
8. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with hematological malignancies. Br J Hematol 2007; 136: 699-712.
9. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liv Dis 2007; 39: 397-408.
10. Raimondo G, Allain J-P, Brunetto MR, Buendia MA, Chen DS, Colombo M et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657.
11. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170.
12. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-837.
13. Dhedin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: A retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66: 616-619.
14. Seth P, Alrajhi AA, Kagevi I, Chaudhary MA, Colcol E, Sahovic E et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versushost disease. Bone Marrow Transplant 2002; 30: 189-194.
15. Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 925-929.
16. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619.
17. Goyama S, Kanda Y, Nannya Y, Kawazu M, Takeshita M, Niino Met al. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk Lymphoma 2002; 43: 2159-2163.
18. Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: High risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007; 14: 478-483.
19. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1049-1059.
20. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-838.
21. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S et al. Performance of a new clinical grading system for chronic graft-versus-host disease: A multicenter study. Blood 2003; 102: 802-809.
22. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Micobiol 2000; 38: 702-707.
23. Chen P-M, Fan S, Liu JH, Chiou TJ, Hsieh SR, Liu RS et al. Reactivation of hepatitis B virus in two chronic GVHD patients after transplant. Int J Hematol 1993; 58: 183-188.
24. Kostaridou S, Ladis V, Kattamis A, Laras A, Hadziyannis SJ. HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Bone Marrow Transplant 1998; 22: 919-921.
25. Iwai K, Tashima M, Itoh M, Okazaki T, Yamamoto K, Ohno H et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000; 25: 105-108.
26. Sakamaki H, Sato Y, Mori SI, Ohashi K, Tanikawa S, Akiyama H et al. Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 342-346.
27. Gonzalez M, Règine V, Piccinini V, Vulcano F, Giampaolo A, Hassan HJ. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion 2005; 45: 1670-1675.
28. Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologus bone marrow transplantation. Bone Marrow Transplant 1989; 4: 207-208.
29. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: Case report and review of the literature. Clin Infect Dis 2005; 41: 1277-1282.
30. Martin BA, Rowe JM, Kouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: Case report and review of literature. Bone Marrow Transplant 1995; 15: 145-148.
31. Li Volti S, Pizzarelli G, Galimberti M, Di Gregorio F, Romeo MA, Lucarelli G et al. Clinical and biochemical reactivation of HBV infection in a thalassemic patient after bone marrow transplantation. Infection 1998; 26: 58-60.
32. Nordbo SA, Skaug K, Holter E, Waage A, Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 2000; 65: 86-87.
33. Hashino S, Nozowa A, Izumiyama K, Yonezumi M, Chiba K, Kondo T et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 29: 361-363.
34. Picardi M, Selleri C, De Rosa G, Raiola A, Pezzullo A, Rotoli B. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 1267-1269.
35. Imamura T, Yokosuka O, Chiba T, Kanda T, Kojima H, Fukai K et al. Lamivudine treatment in a patient with hepatitis B virus reactivation after allogeneic peripheral bone marrow transplantation. Leuk Lymphoma 2005; 46: 915-917.
36. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
37. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.